Amylyx Pharmaceuticals Inc
NASDAQ: AMLX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Amylyx Pharmaceuticals Inc (AMLX) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $1.43M | $-14.82M | -734.43% | -950.49% | -1,038.99% |
| 2020 | $650000.00 | $-42.28M | -3,683.69% | -6,000.77% | -6,504.62% |
| 2021 | $285000.00 | $-87.88M | 100.00% | -29,013.33% | -30,834.74% |
| 2022 | $22.23M | $-198.38M | 86.54% | -905.72% | -892.38% |
| 2023 | $380.79M | $49.27M | 93.32% | 10.19% | 12.94% |
| 2024 | $87.37M | $-301.74M | 51.75% | -360.22% | -345.36% |
| 2025 | $0.00 | $-144.74M | — | — | — |
Frequently asked questions
What is Amylyx Pharmaceuticals Inc's revenue?
Amylyx Pharmaceuticals Inc's trailing twelve-month revenue is $-665000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does AMLX generate?
AMLX produced $-123.48M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is AMLX's balance sheet healthy?
AMLX holds $226.65M in cash and equivalents against — in long-term debt, on $305.26M of shareholder equity. That debt is best read against the cash flow the business throws off each year.